Results 221 to 230 of about 22,889 (244)

Development of a highly stable and targetable nanoliposomal formulation of topotecan

Journal of Controlled Release, 2010
Daryl C Drummond, Mark E Hayes, John W Park   +2 more
exaly  

A Dose-Escalating Study of Weekly Bolus Topotecan in Previously Treated Ovarian Cancer Patients

Gynecologic Oncology, 2001
David A Martin, Luis Vaccarello, William A Nahhas   +2 more
exaly  

Topotecan

Der Onkologe, 1998
R. Kath, H. D. Peters, C.-P. Schneider, K. Höffken   +3 more
openaire   +1 more source

Urinary and fecal excretion of topotecan in patients with malignant solid tumours

Cancer Chemotherapy and Pharmacology, 2002
Wim W Ten Bokkel Huinink, Jan H M Schellens, Jos H Beijnen   +2 more
exaly  

Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage

European Journal of Pharmacology, 2001
Friederike Schmidt, Johannes Rieger, Jörg Wischhusen   +2 more
exaly  

Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma

European Journal of Cancer, 2011
Maria Antonietta De Ioris, Aurora Castellano, Maria Carmen Garganese   +2 more
exaly  

Topotecan

Reactions Weekly, 2018
openaire   +1 more source

Tracking the cell cycle origins for escape from topotecan action by breast cancer cells

British Journal of Cancer, 2003
R J Errington, Paul J Smith, Smith P J
exaly  

Phase II evaluation of topotecan in carcinosarcoma of the uterus: A Gynecologic Oncology Group study

Gynecologic Oncology, 2005
David S Miller, John A Blessing, Adnan Munkarah   +2 more
exaly  

Intravitreal topotecan in the management of refractory and recurrent vitreous seeds in retinoblastoma

British Journal of Ophthalmology, 2017
R. Rao, S. Honavar, Vishal R. Sharma, V. Reddy   +3 more
semanticscholar   +1 more source